Maple Grove, MN – August 27, 2019 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Morphine Sulfate Tablets, CII, 15 and 30 mg. The morphine sulfate tablet market had U.S. sales of approximately $49 million for the 12 months ending June 2019 according to IQVIA.
|Product||Strength||NDC #||Package Size|
|Morphine Sulfate Tablets, CII||15 mg||0832-0273-11||100 ct|
|Morphine Sulfate Tablets, CII||30 mg||0832-0274-11||100 ct|
For questions about ordering, please call Upsher-Smith at 1-800-654-2299.
|WARNING: ADDICTION, ABUSE, AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION;ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS
See full prescribing information for complete boxed warning.
Please refer to the full Prescribing Information, including Boxed Warning for Morphine Sulfate Tablets, CII here. You can also call 1-888-650-3789 to obtain a copy of the full Prescribing Information.
Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.
As Upsher-Smith celebrates its 100-year anniversary, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai Pharmaceutical Co., Ltd. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients they serve. For more information, visit
Do More Good is a trademark of Upsher-Smith Laboratories, LLC